Brind.
  1. Immunovant, Inc. presented new company data at the meeting of the American Thyroid Association (ATA).

Immunovant developed and tested batoclimab, which is currently being studied for the treatment of Graves’ disease.

1 report, 1 independent Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Immunovant developed and tested batoclimab, which is currently being studied for the treatment of Graves’ disease.

Keep exploring

Part of

Immunovant, Inc. presented new company data at the meeting of the American Thyroid Association (ATA). All 1 developments

Coverage

Newest first; wire copies grouped
  • ZacksIMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results Immunovant, Inc. IMVT shares gained 10.8% on Wednesday after the company announced new six-month off-treatment results from a proo